Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardised and AI-supported workflow to optimise quality and response times, initially within prostate.
World-leading cancer diagnostics for everyone
World-leading
cancer diagnostics
for everyone
Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardised and AI-supported workflow to optimise quality and response times, initially within prostate.
How can an ultramodern laboratory, 100% specialized in uropathology, benefit you and your patients?
Welcome to our booth at Urologidagarna in Malmö, October 5–7. Let’s talk about how you can get visual and intuitive pathology reports within 5 days with high and consistent quality, created by world-leading AI in collaboration with experienced uropathologists.
Your patient, our priority
Urologidagarna i Malmö, booth #43
Malmö Live
October 5–7, 2022
Malmö Live
October 5–7, 2022
Learn more about Inify Laboratories
Watch the video presentation
From our customers
CUSTOMER CASE | Capio Urosurgical Centre
“We had issues with long lead times for prostate biopsies. Inify provides results within 5 working days - that's the main reason we partnerd with them”.
Martin Bergman
Consultant Urologist,
CEO and founder
CEO and founder
CUSTOMER CASE | Urologifocus
“Partnering with Inify has saved us time - we no longer need to call pathologists about missing results or reschedule patients due to reporting delays”.
Elin Weilow
Specialist Nurse,
Co-founder
Co-founder
CUSTOMER CASE | Capio Urology Centre
“Since sending our samples to Inify, we’ve reduced the time from biopsy to results from 21 to 7 days, enabling us to schedule follow-ups much earlier”.
Thomas Hopfgarten
Consultant Urologist,
CEO
CEO
PANEL TALK
Inify cuts diagnostic waiting times by weeks – now entering the UK market: Panel talk Q2 report 2025
“It’s all about pathways. By supporting the entire clinical pathway for prostate cancer – from the urology department to the pathology department – we generate measurable efficiency and quality gains across the patient pathway, ultimately delivering faster and better care for every patient,” says Fredrik Palm. Listen to the panel talk led by Ole Eikeland with Inify’s CEO Fredrik Palm.
One out of seven will be diagnosed with prostate cancer
Handling of prostate biopsies makes up an increasing amount of workload for today’s pathology labs. Here, powerful decision support tools – such as Inify Prostate – have the potential to save valuable time for the pathologist, while ensuring a more objective, consistent and accurate evaluation of the biopsies.
PANEL TALK
Over 1,000 patients diagnosed: Panel talk Q2 report 2024
Inify reports sales of SEK 3.6 million in the quarter – up 62% compared to Q1. By the end of June, the laboratory had been open for over a year and had diagnosed more than 1,000 patients. More details about the laboratory operations and its success factors are discussed in a panel talk led by Ole Eikeland with Inify’s CEO Fredrik Palm and Laboratory Director Emelie Edvigsson.
CUSTOMER CASE | Urologifocus
Saved time and improved workflow
“The main difference for us since we started working with Inify is the time we save. Previously, we often had to call the pathology department to ask about missing test results and contact patients to reschedule due to delays. Now, we don’t have to deal with that at all.”
Elin Weilow,
Specalist nurse
Urologifocus
Specalist nurse
Urologifocus
Coming soon
Friday, August 29th at 13:00
Panel talk about Inify’s second quarter 2025

Coming soon
Wednesday, April 16th at 08:00
Inify’s Annual Report 2024

-
Investor News
News





